Aimovig
erenumab
Table of contents
Overview
Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.
Aimovig contains the active substance erenumab.
-
List item
Aimovig : EPAR - Summary for the public (PDF/72.56 KB)
First published: 08/08/2018
Last updated: 06/05/2019 -
-
List item
Aimovig : EPAR - Risk-management-plan summary (PDF/139.57 KB)
First published: 08/08/2018
Last updated: 08/08/2018
This EPAR was last updated on 09/09/2020
Authorisation details
Product details | |
---|---|
Name |
Aimovig
|
Agency product number |
EMEA/H/C/004447
|
Active substance |
erenumab
|
International non-proprietary name (INN) or common name |
erenumab
|
Therapeutic area (MeSH) |
Migraine Disorders
|
Anatomical therapeutic chemical (ATC) code |
N02CX07
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Novartis Europharm Limited
|
Revision |
5
|
Date of issue of marketing authorisation valid throughout the European Union |
26/07/2018
|
Contact address |
Product information
25/08/2020 Aimovig - EMEA/H/C/004447 - PSUSA/00010699/201911
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Analgesics
Therapeutic indication
Therapeutic indication
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.